Compliant Pharmacy Alliance appoints VP marketing
STOUGHTON, Wis. — A pharmacy purchasing cooperative announced that Mark LaPorte has joined its team as VP marketing.
In his new role at Compliant Pharmacy Alliance, LaPorte will focus on coordinating and facilitating CPA membership growth and retention, recruiting, communications and marketing. An industry veteran, LaPorte has more than 25 years of experience in sales, sales management, sales training and marketing in the healthcare industry.
“The addition of Mark to our marketing team further strengthens our ability to continue the rapid growth CPA has enjoyed over the years," CPA CEO Ed Heckman said. "Mark’s comprehensive marketing and sales management experience will greatly benefit CPA and our co-op membership.”
FTC issues ‘second request’ to Teva, Cephalon over deal
JERUSALEM and FRAZER, Pa. — Before they can move ahead with their deal, drug makers Teva and Cephalon must provide the Federal Trade Commission with additional information related to Teva’s pending acquisition of Cephalon.
The "second request," as it often is called, is to extend the Hart-Scott-Rodino Antitrust Improvements Act of 1976 waiting period until thirty days after the parties substantially have complied with the request, the FTC said. Teva and Cephalon said they are in full cooperation with the FTC and continue to expect the acquisition will be completed in third quarter 2011.
As previously reported by Drug Store News, generic drug maker Teva said that it would buy Frazer, Pa.-based Cephalon for $6.8 billion in May.
GPhA: Including provisions relating to biologics in TPP agreements is ‘premature’
WASHINGTON — The country’s largest trade group for generic drug companies is concerned that the government’s negotiations on the Trans-Pacific Partnership agreement could hinder competition and access to generic drugs.
The Generic Pharmaceutical Association sent a letter to President Barack Obama Tuesday saying that provisions relating to intellectual property rights for biotech drugs should not be included in the TPP, a proposed regional trade agreement for the Asia-Pacific region.
The GPhA noted that while implementation of a regulatory approval pathway for biosimilars is ongoing at the Food and Drug Administration, significant disagreement remains about how the law should be implemented and whether further legislation is necessary.
“Given your administration’s position and the uncertainty surrounding the pathway’s implementation by [the] FDA, as well as the critical need to ensure access to safe and affordable medicines in global markets, it is premature to include provisions relating to biologics in any trade agreement,” GPhA executive director Bob Billings wrote in the letter.